About a year after starting to work, albeit indirectly, with the vaccine platform developed by Affinivax Inc., Astellas Pharma Inc. was sufficiently impressed to come back for seconds. The companies inked a global license arrangement for Affinivax's lead vaccine candidate, targeting Streptococcus pneumoniae, that included $10 million in up-front funding.